Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

menu
Jainulabdeen J. Ifthikharuddin, M.B.B.S.
Jainulabdeen J. Ifthikharuddin, M.B.B.S.

Jainulabdeen J. Ifthikharuddin, M.B.B.S.

Medicine — Hematology/Oncology — Hematology

Accepting New Patients

Jainulabdeen J. Ifthikharuddin, M.B.B.S.

Medicine — Hematology/Oncology — Hematology

Accepting New Patients


Locations

James P. Wilmot Cancer Center
601 Elmwood Ave.
Rochester, NY 14642
Get Directions

phone

Appointments

(585) 275-5823

print

Fax

(585) 273-1042

About Me

As an oncologist, my goal is to deliver high-quality, comprehensive and compassionate care that is suited to each patient's unique needs.

I have a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. In addition to my clinical and teaching responsibilities, I am an active participant in several myeloma-related clinical trials.

Conditions I Treat

- Myeloma
- Monoclonal gammopathies
- Amyloidosis

Dr. Ifthikharuddin admits to:

Strong Memorial Hospital
Highland Hospital

Credentials

Education:

MD | Madras Medical College — 1985

Post-doctoral Training & Residency:

Fellowship in Hematology/Oncology at University of Rochester Medical Center — 1996 - 1999
Residency in Internal Medicine at University of Rochester Medical Center — 1994 - 1996
Internship in Rotating internship at Government General Hospital — 1985 - 1986

Research

Dr. Ifthikharuddin has a special interest in the treatment of multiple myeloma and other plasma cell dyscrasias. He graduated from the Madras Medical College, India, followed by additional training in the United Kingdom, culminating in diplomas from the Royal College of Physicians (MRCP) and Hematology (MRC Path). He subsequently completed residency training in Internal Medicine and fellowship in Hematology/Oncology at The University of Rochester and joined the faculty in the year 2000. He is board certified in Hematology. In addition to clinical and teaching responsibilities, he is an active participant in several clinical trials.

Publications:

Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikaruddin JJ, Mulford D, Chen R, Bechelli J, Roswell K, Minhajuddin M, Jordan CT, Phillips Gl 2nd. "A phase I study of decitabine and rapamycin in relapsed/refractory AML". Leukemia Research. 2013; 37(12): 1662-7.

Milner LA; Becker MW; Bernstein SH; Bruckner L; Friedberg JW; Holland GA; Ifthikharuddin JJ; LIesveld JL; Mathes EJ; Mechel HL; Mullen CA; Sasson T; Phillips GL 2nd. "Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease". Am J Hematology. 2011; 86(8): 712-714.

Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips GL 2nd. "Proteasome inhibition in myelodysplastic syndromes and acute myelogeneous leukemia cell lines". Cancer Invest. 2011; 29(7): 438-450.

View All Publications